<unk>  vary by the type of<unk> , stage at diagnosis, treatment given and many other factors, including country. In general<unk><unk>  are improving, although more so for some<unk> s than others.<unk> <unk> can be measured in several ways, median life expectancy having advantages over others in terms of meaning for people involved, rather than as an epidemiological measure. However,<unk><unk>  are currently often measured in terms of 5-year<unk><unk> , which is the percentage of people who live at least five years after being diagnosed with<unk> , and relative<unk><unk>  compare people with<unk>  to people in the overall population. Several types of<unk>  are associated with high<unk><unk> , including breast, prostate, testicular and colon<unk> . Brain and pancreatic<unk> s have much lower median<unk><unk>  which have not improved as dramatically over the last forty years. Indeed, pancreatic<unk>  has one of the worst<unk><unk>  of all<unk> s. Small cell lung<unk>  has a five-year<unk> <unk> of 4% according to<unk>  Centers of America's Website. The American<unk>  Society reports 5-year relative<unk><unk>  of over 70% for women with stage 0-III breast<unk>  with a 5-year relative<unk> <unk> close to 100% for women with stage 0 or stage I breast<unk> . The 5-year relative<unk> <unk> drops to 22% for women with stage IV (metastatic) breast<unk> . In<unk>  types with high<unk><unk> , incidence is usually higher in the developed world, where longevity is also greater.<unk> s with lower<unk><unk>  are more common in developing countries. The highest<unk>  are in countries such as South Korea, Japan, Israel, Australia, and the United States.
Cancer survival rates
Survival rate
Cancer research
Disease burden
Men's health
Drug Safety
Women's health
Prevalence of mental disorders